Clinical Trial Update: Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating whether an EPA-rich enteral nutrition improves outcomes in patients receiving chemotherapy for gastric or colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• EPA-enriched enteral nutrition (eicosapentaenoic acid)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Gastric Cancer, Colorectal Cancer | Phase 3 | Status: UNKNOWN